Firefly Neuroscience (NASDAQ:AIFF) Cut to Sell at Wall Street Zen

Wall Street Zen lowered shares of Firefly Neuroscience (NASDAQ:AIFF) from a hold rating to a sell rating in a report released on Saturday.

Separately, Weiss Ratings upgraded Firefly Neuroscience from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Tuesday, May 19th. One investment analyst has rated the stock with a Sell rating, Based on data from MarketBeat.com, Firefly Neuroscience has an average rating of “Sell”.

Firefly Neuroscience Price Performance

Shares of AIFF stock opened at $1.13 on Friday. The company has a market capitalization of $17.73 million, a P/E ratio of -1.92 and a beta of 0.57. The company’s 50-day simple moving average is $1.24 and its two-hundred day simple moving average is $1.46. Firefly Neuroscience has a one year low of $0.62 and a one year high of $3.63.

Firefly Neuroscience (NASDAQ:AIFF) last released its quarterly earnings data on Monday, August 10th. The company reported ($0.10) earnings per share for the quarter. The business had revenue of $0.51 million during the quarter. Firefly Neuroscience had a negative return on equity of 90.17% and a negative net margin of 506.23%.

Institutional Investors Weigh In On Firefly Neuroscience

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in AIFF. Jane Street Group LLC acquired a new stake in Firefly Neuroscience in the fourth quarter worth about $53,000. Geode Capital Management LLC grew its stake in shares of Firefly Neuroscience by 92.9% during the second quarter. Geode Capital Management LLC now owns 120,604 shares of the company’s stock worth $341,000 after acquiring an additional 58,067 shares during the last quarter. BlackRock Inc. purchased a new stake in Firefly Neuroscience in the second quarter valued at approximately $226,000. Finally, Vanguard Group Inc. increased its holdings in Firefly Neuroscience by 393.3% in the 3rd quarter. Vanguard Group Inc. now owns 503,071 shares of the company’s stock worth $1,464,000 after buying an additional 401,085 shares during the period. 4.96% of the stock is currently owned by hedge funds and other institutional investors.

Firefly Neuroscience Company Profile

Firefly Neuroscience is a clinical?stage neurotechnology company focused on developing digital biomarkers and cognitive assessment tools for the early detection and monitoring of neurological disorders. The company’s platform combines mobile applications, sensor technology and advanced analytics to capture objective brain function data outside of traditional clinical settings. By providing real?world cognitive and physiological measurements, Firefly aims to improve diagnosis, track disease progression and support therapeutic development.

The company’s flagship offering is a smartphone?based cognitive assessment app that guides users through a series of interactive tasks designed to measure attention, memory, processing speed and executive function.